Clinical Trial Update: CBD for Individuals at Risk for Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cannabidiol (CBD) for individuals with mild cognitive impairment at risk of Alzheimer's disease. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Cannabidiol (CBD) (cannabidiol)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Mild Cognitive Impairment | Phase 2 | Status: RECRUITING